Alerta

INSULIN INFUSION SET

Resumen de: US20260284305A1

0000 Embodiments of devices and methods to maintain preservative concentration in a medication delivered using a medical device are provided. A barrier layer can be used to prevent migration of preservatives. A vent can be used to allow release of preservatives prior to delivery to the patient. An absorbent element can be used to maintain preservative concentration at a desired level. A filter can be used to capture particulates from the medication prior to delivery to a patient.

USING CONTINUOUS BIOMETRIC INFORMATION MONITORING FOR SECURITY

Resumen de: US20260288926A1

0000 Measurements of biometric information of a user are obtained over time, such as blood glucose measurements. These biometric measurements are typically obtained by a wearable biometric information monitoring device being worn by the user. These biometric measurements are used by various different systems, such as a computing device of the user or a biometric information monitoring platform that receives biometric measurements from multiple different users. The biometric measurements are used for various security aspects, such as one or more of part of multi-factor authentication of the user, generating security keys (e.g., connection keys, encryption keys), identifying biometric measurements associated with different user identifiers but the same use, and protecting biometric measurements so as to be retrievable only by a recipient associated with an additional computing device, and so forth.

METHODS AND SYSTEM FOR OPTOGENETIC STIMULATION OF ADIPOCYTES

Resumen de: US20260284229A1

Provided herein are, inter alia, methods, compositions, and kits for inducing thermogenesis in adipocyte populations. Also included are methods and compositions for increasing thermogenesis in adipocyte populations (e.g., brown/beige/white adipocyte populations) in a subject, as well as methods and compositions for treating subjects who are overweight, obese, or who have diabetes.

CELL THERAPIES FOR TYPE 1 DIABETES

Resumen de: US20260285937A1

0000 The present disclosure is directed to T cell receptors targeting GAD65 and isolated cell populations comprising regulatory T cells exogenously expressing said TCRs used to treat Type 1 Diabetes.

TCR WITH HIGH AFFINITY AND SPECIFICITY SPECIFIC FOR PREPROINSULIN PEPTIDE ALWGPDPAAA BOUND TO HLA-A2*02

Resumen de: US20260285984A1

The present invention relates to binding molecules comprising a peptide-major histocompatibility complex (pMHC)-binding domain which binds to a ALWGPDPAAA (SEQ ID NO: 1) peptide (derived from human pre-pro insulin (PPI) protein) presented as a peptide-HLA-A*02 complex. Said binding molecules may comprise CDR sequences embedded within a framework sequence. The CDRs and framework sequences may correspond to a T cell receptor (TCR) variable domain and may further comprise non-natural mutations relative to a native TCR variable domain. The binding molecules of the invention have high affinity and high specificity for the ALWGPDPAAA (SEQ ID NO: 1)-HLA-A*02 complex. The binding molecules may further comprise an immune suppressor and/or a half-life extending domain. Such binding molecules are particularly useful in the development of soluble immunotherapeutic reagents for the treatment of autoimmune diseases, such as diabetes.

ENGINEERED IMMUNE CELLS FOR TREATING CANCER IN COMBINATION WITH IL-2/IL-15 RECEPTOR BETA-GAMMA AGONISTS

Resumen de: US20260284145A1

0000 A combined therapy for treating cancer in a subject, comprising an immune cell population and an Interleukin-2/Inter-leukin-15 receptor beta gamma (IL-2/IL-15Rβγ) agonist. The immune cell population comprises genetically engineered immune cells expressing or overexpressing a metabolism-regulating polypeptide, which may (a) improves glucose uptake activity; (b) modulates the Krebs cycle; (c) enhances lactate concentration; and/or (d) diverts or redirects glucose metabolites out of a glycolysis pathway.

ADIPOCYTE GROWTH INHIBITOR

Resumen de: US20260283977A1

ProblemThe present invention provides a useful treatment tool for obesity-related adipogenesis using DHMBA. DHMBA-containing culture suppresses the growth of 3T3-L1 preadipocytes in vitro, leading to a reduction in the number of cells. In an adipocyte differentiation process, culture in the presence of DHMBA suppresses adipogenesis in the process of differentiation of 3T3-L1 preadipocytes into adipocytes through the regulation of various signaling processes associated with insulin signaling.SolutionThe present invention includes 3,5-dihydroxy-4-methoxy benzyl alcohol (DHMBA) as an active ingredient and has an inhibitory action on 3T3-L1 preadipocyte growth.

SYSTEM AND METHOD FOR INFUSION SET DISLODGEMENT DETECTION

Resumen de: US20260284326A1

A portable insulin pump can utilize readings from a sensor incorporated into an infusion set used with the pump to deliver insulin to a patient to determine if the infusion set is or is likely to become dislodged from the patient. Readings from the sensor that are inconsistent with expected readings or a range of expected readings can indicate that the infusion set has become dislodged from the patient.

NETWORK TOPOLOGY FOR INSULIN PUMP SYSTEMS

Resumen de: EP4811834A2

In one implementation, an insulin delivery system using an on-body network includes an insulin delivery device that is adapted to administer dosages of insulin to a patient; a controller that is adapted to control operation of the insulin delivery device, to establish a first network connection in which the controller acts in a central role, and to establish a second network connection in which the controller acts in a peripheral role; one or more peripheral devices that are adapted to generate patient data related to blood glucose levels and to transmit the patient data wirelessly over the first network connection, the peripheral devices acting in a peripheral role over the first network connection; and a mobile application installed on a mobile computing device that is programmed to communicate with the controller over the second network connection, the mobile application communicating in a central role over the second network connection.

WIRELESS GLUCOSE MONITORING SYSTEM WITH DYNAMIC COMMUNICATION MANAGEMENT

Resumen de: WO2025106280A1

Techniques are provided for dynamically managing wireless communications of glucose monitoring systems. The systems dynamically adjust the communication session intervals based on various dynamic conditions. Some systems are also configured with an antenna positioned on an opposing side of a chip from other sensor electronics and/or outside of an encasing of potting material to enhance the signaling functionality of the antenna.

PERSONALIZED CLOSED-LOOP ARTIFICIAL PANCREAS SYSTEM

Resumen de: EP4810079A1

0001 The invention discloses a personalized closed-loop artificial pancreas system, comprising: a detection mechanism, an infusion mechanism, and a program mechanism, at least based on the blood glucose value detected by the detection mechanism, the program mechanism generates an insulin infusion instruction and controls the infusion mechanism to perform the infusion, the program mechanism comprises a user interface, and in response to an input from the patient, the program mechanism performs a corresponding meal mode function, the meal mode comprises a high carbohydrate mode and a normal carbohydrate mode. Based on the patient's input, the program mechanism executes the functions of high carbohydrate mode or normal carbohydrate mode, which can be suitable for people with different carbohydrate consumption habits, improve the adaptability of closed-loop artificial pancreas to different populations, and enable people with different carbohydrate consumption habits to maintain satisfactory blood glucose control effects.

COMPATIBILITY CHECK FOR CONTINUOUS GLUCOSE MONITORING APPLICATION

Resumen de: EP4809909A2

0001 Disclosed are systems, methods, and articles for determining compatibility of a mobile application and operating system on a mobile device. In some aspects, a method includes receiving one or more data values from a mobile device having a mobile medical software application installed thereon, the data value(s) characterizing a version of the software application, a version of an operating system installed on the mobile device, and one or more attributes of the mobile device; determining whether the mobile medical software application is compatible with the operating system by at least comparing the received data value(s) to one or more test values in a configuration file; and sending a message to the mobile device based on the determining, the message causing the software application to operate in one or more of a normal mode, a safe mode, and a non-operational mode.

Stabilisation medium for extending temporal viability of human semen

Resumen de: GB2704849A

A stabilization medium (optionally having a pH between 7.2-8) for extending temporal viability of human semen for up to a predetermined time period when mixed therewith and maintained within a predetermined temperature range, comprising: one or more pH buffer agents (optionally comprising MOPS or HEPES in a concentration range of 10.0-25.0 mmol); one or more inorganic salts (optionally selected from sodium chloride, potassium chloride, magnesium sulfate heptahydrate, sodium phosphate dihydrate, sodium bicarbonate and calcium chloride dihydrate); one or more organic compounds (optionally selected from glucose, sodium lactate (L-isomer), sodium pyruvate and taurine); and one or more amino acids with antioxidant properties (optionally selected from alanine, aspartate, asparagine, glutamate, alanyl-glutamine, glycine, proline and serine). The stabilization medium may further comprise at least one of: one or more antioxidants (selected from a group comprising acetyl-L-carnitine, alpha-lipoic acid and N-acetyl-L-cysteine); one or more pH-altering compounds (selected from a group comprising sodium dihydrogen phosphate dihydrate, magnesium sulfate heptahydrate, calcium chloride dihydrate, sodium lactate (L-isomer) and sodium pyruvate); one or more antibiotics and chelating agents. The predetermined time period may be up to 72 hours and the predetermined temperature range may be 36.1-37.2 degrees Celsius. Figure 2

WIRELESS GLUCOSE MONITORING SYSTEM WITH REPLACEABLE TRANSMITTER PATCH

Resumen de: WO2025106281A1

Sensor systems are provided that include (i) a sensor configured to obtain sensor data indicative of an analyte level of a user's body, (ii) a first transmitter patch configured in size and shape to overlay the sensor during a first time period of use, (iii) a second transmitter patch configured in size and shape to overlay the sensor during a second time period of use. First sensor data is transmitted from the sensor to the first transmitter patch corresponding to the first time period and second sensor data is transmitted from the sensor to the second transmitter patch corresponding to the second time period. The first transmitter patch can be replaced by the second transmitter patch without removing the sensor.

CONTINUOUS BLOOD SUGAR MEASURING DEVICE

Resumen de: EP4809921A2

0001 The present disclosure relates to a continuous blood sugar measuring device, and provides a continuous blood sugar measuring device which is capable of minimizing additional work of a user in order to attach a body attachment unit, by manufacturing the body attachment unit to be assembled inside an applicator so that the body attachment unit can be attached to the body simply by operating the applicator and, particularly: communicating with an external terminal by providing a wireless communication chip in the body attachment unit so that simple and convenient use is possible and maintenance can easily be performed without the additional work of connecting a separate transmitter; initiating operation by a manipulation of the user, after attaching the body attachment unit to the body, so that an operation initiation time can be adjusted to a suitable time according to the need of the user; and initiating operation in a stabilized state to enable a more accurate measurement of blood sugar.

SYSTEM AND METHOD FOR WIRELESS COMMUNICATION OF GLUCOSE DATA

Resumen de: US2018027104A1

Systems, devices, and methods are disclosed for wireless communication of analyte data. One such method includes, during a first interval, establishing a first connection between an analyte sensor system and a display device. During the first connection, the method includes exchanging information related to authentication between the analyte sensor system and the display device. The method includes making a determination regarding whether authentication was performed during the first interval. During a second interval, the method may include establishing a second connection between the analyte sensor system and the display device for transmission of an encrypted analyte value, and bypassing the exchanging of information related to authentication performed during the first connection. The method also includes, during the second interval, the analyte sensor system transmitting the encrypted analyte value to the display device, if the determination indicates that the authentication was performed during the first interval.

AUTOMATED SCREENING FOR DIABETIC RETINOPATHY SEVERITY USING COLOR FUNDUS IMAGE DATA

Resumen de: US20260279578A1

Methods and systems for evaluating diabetic retinopathy (DR) severity are provided herein. Color fundus imaging data is received for an eye being evaluated for DR. A metric is generated using the color fundus imaging data, the metric indicating a probability that a score for the DR severity in the eye falls within a selected range.

SOLUTION FOR SUSPENDING CELLS, AND USE THEREOF

Resumen de: US20260275287A1

An object of the present invention is to provide a solution for thawing that can maintain or improve the cytotoxic activity of highly active NK cells and the like after thawing. A solution for suspending cells for administration to humans, which satisfies the following criteria: (1) containing potassium ion, (2) having a pH of 4.9 or higher, (3) not containing chloride ions at a concentration of 135 mEq/L or higher, (4) not containing glucose at a concentration of 5.55 mM or higher, (5) not containing calcium ions at a concentration of 0.423 mM or higher, (6) having an osmolarity of 200 to 396 mOsm, and (7) containing any organic acid(s) selected from the group consisting of succinic acid, malic acid, lactic acid, citric acid, and acetic acid.

MATURATION MEDIUM COMPOSITIONS AND METHODS FOR HUMAN HEART ORGANOID MATURATION

Resumen de: US20260275292A1

A maturation medium and a method for maturing an early embryonic human heart organoid into a mature human heart organoid are provided herein. The maturation medium includes a cell growth medium containing a medium supplement including one or more fatty acid, triiodothyronine (T3) growth hormone, insulin, one or more antioxidant, a sugar, and carnitine; one or more additional fatty acid; an additional carnitine or creatine; and an additional T3 growth hormone. The maturation medium may further include one or more of an additional sugar, an additional antioxidant, and a growth factor. The method includes contacting an early embryonic human heart organoid with one or more maturation medium to produce a mature human heart organoid.

SYSTEMS AND METHODS FOR AN ARTIFICIAL INTELLIGENCE HEALTH COACH WITH BIOMETRIC DATA INTEGRATION AND PERSONALIZED HEALTH INTERVENTION GENERATION

Resumen de: US20260279592A1

A method uses an artificial intelligence health coach system that includes receiving a voice input from a user, interpreting the voice input with natural language processing performed by an artificial intelligence model, which includes a large language model, and receiving a glucose level from a continuous glucose monitor. The method further includes receiving an insulin level from a database, calculating a Homeostatic Model Assessment of Insulin Resistance score from the glucose level and the insulin level, comparing the score to historical scores associated with the user, and identifying a predicted risk of a hyperglycemic episode. The method also includes generating a preventative health recommendation modified based on whether the score has changed over time, requesting additional health information from the user, modifying the recommendation based on the additional information, and outputting the modified recommendation to the user. The method maintains persistent user data as contextual memory across interactions.

METHODS OF ESTIMATING BLOOD GLUCOSE AND RELATED SYSTEMS

Resumen de: US20260276659A1

A method includes estimating a value of a parameter indicative of an age or lifespan of a population of red blood cells of a subject, estimating a value of average glucose (AG) of the subject based on (i) the value of the parameter and (ii) a value indicative of an amount of glycated hemoglobin (HbA1c) of the subject, and providing information for treatment or diagnosis of a hyperglycemia condition of the subject based on the estimated value of AG.

IMPROVED CELL IMPLANTS AND METHODS OF USING THE SAME

Resumen de: WO2026193167A1

The present disclosure provides modified cells for use in cell therapies to treat diabetes, as well as methods for preparing such cells. More specifically, the present disclosure provides genetically modified cells that reduce the production of extracellular matrix following implantation and/or express a novel peptide that targets the cells for destruction without impacting the subject's native cells.

Senolytic car-T cells targeting uPAR, a cell surface and secreted senescence biomarker

Resumen de: AU2026205448A1

Abstract Provided herein are compositions and methods for adoptive cell therapy comprising engineered immune cells that express a uPAR-specific chimeric antigen receptor. Also disclosed herein are methods for using the engineered immune cells of the present technology to treat or ameliorate the effects of cancer and senescence-associated pathologies (e.g., lung fibrosis, atherosclerosis, Alzheimer's disease, diabetes, liver fibrosis, chronic kidney disease, aging, or osteoarthritis) by selectively targeting senescent cells. Also provided herein are methods for detecting the senescent cell burden in a patient. Abstract

METHODS OF EVADING IMMUNE REJECTION

Resumen de: US20260273059A1

The present disclosure is directed to methods, compositions and devices capable of avoiding foreign body responses to implanted material. This technology utilizes polymer encapsulated engineered cells that produce natural, cell-generated cytokines to elicit a tailored immune response to implanted materials for applications in diabetes, immune tolerance, and organ transplantation.

TECHNIQUES FOR DETERMINING AUTOMATED INSULIN DELIVERY DOSAGES

Nº publicación: US20260273184A1 17/09/2026

Solicitante:

INSULET CORP [US]
INSULET CORPORATION

Resumen de: US20260273184A1

Methods and apparatuses for performing an insulin infusion process are described. For example, an apparatus may include at least one memory and logic coupled to the at least one memory. The logic may operate to determine a basal parameter for a patient based on a type 2 diabetes (T2D) multiple daily injection (MDI) information of the patient, the basal parameter indicating a basal infusion rate, determine an additional insulin (Iadd) value based on a mean blood glucose difference (BGdiff) information associated with the patient, determine an insulin volume to infuse into the patient based on the basal parameter and Iadd, and administer the insulin volume to the patient. Other embodiments are described.